辉瑞疫苗接种后出现米勒费雪综合征：一项范围综述。
Miller Fisher syndrome following COVID-19 vaccines: A scoping review.
机构信息
Department of Neurology, Ewha Womans University College of Medicine, Seoul, Korea.
Department of Neurology, Dong-A University College of Medicine, Busan, Korea.
出版信息
Acta Neurol Scand. 2022 Nov;146(5):604-609. doi: 10.1111/ane.13687. Epub 2022 Aug 8.
BACKGROUND AND PURPOSE
Miller Fisher syndrome (MFS), a variant of Guillain-Barré Syndrome (GBS), could be underestimated in evaluations of its adverse events (AEs) following COVID-19 vaccination. We aimed to identify and characterize MFS following COVID-19 vaccination.
MATERIALS AND METHODS
Relevant studies reported on during the COVID-19 pandemic were identified in the MEDLINE, Embase, and other databases.
RESULTS
Nine cases of MFS following COVID-19 vaccination from various regions were included. Unlike MFS following COVID-19 infection, patients with MFS following COVID-19 vaccination frequently presented with anti-GQ1b antibody positivity (44%, 4/9). Unlike GBS following COVID-19 vaccination, only two of nine (22%) cases of MFS following COVID-19 vaccination had developed after viral-vector-related vaccine administration.
CONCLUSIONS
Miller Fisher syndrome following COVID-19 vaccination seems to have a different pathophysiology from MFS following COVID-19 infection and GBS following COVID-19 vaccination. This neurological syndrome with a rare incidence and difficulty in diagnosis should be considered an AE of COVID-19 vaccination.
背景与目的
Miller Fisher 综合征（MFS）是吉兰-巴雷综合征（GBS）的一种变异型，在评估 COVID-19 疫苗接种后的不良事件（AE）时可能被低估。我们旨在确定和描述 COVID-19 疫苗接种后的 MFS。
材料与方法
在 COVID-19 大流行期间，我们在 MEDLINE、Embase 和其他数据库中确定了相关报道的研究。
结果
纳入了来自不同地区的 9 例 COVID-19 疫苗接种后 MFS 病例。与 COVID-19 感染后 MFS 不同，COVID-19 疫苗接种后 MFS 患者常表现为抗 GQ1b 抗体阳性（44%，4/9）。与 COVID-19 疫苗接种后 GBS 不同，COVID-19 疫苗接种后仅有 9 例 MFS 中的 2 例（22%）发生在病毒载体相关疫苗接种后。
结论
COVID-19 疫苗接种后 MFS 的发病机制似乎与 COVID-19 感染后 MFS 和 COVID-19 疫苗接种后 GBS 不同。这种罕见且诊断困难的神经系统综合征应被视为 COVID-19 疫苗接种的 AE。
Zotero 插件